Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.44 |
| ▸ | ACHE known ✓ | P22303 | 7/20 | 0.40 |
| ▸ | CHRNA7 | P36544 | 5/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.39 |
| ▸ | CCR5 | P51681 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL321885 | 0.98 | CHRNA7 (0.48) | CHRNA7CHRM3CHRNB2CHRNA4ACHE | |
| Bromide SCHEMBL1140066 | 0.96 | CHRNA7 (0.50) | CHRNA7CHRM3CHRNB2CHRNA4ACHE | |
| SCHEMBL8346963 | 0.90 | CHRNA7 (0.43) | CHRNA7CHRM3CHRNB2CHRNA4ACHE | |
| SCHEMBL4258543 | 0.89 | CHRNA7 (0.42) | CHRNA7CHRM3CHRNB2CHRNA4ACHE | |
| SCHEMBL10256548 | 0.87 | CHRNA7 (0.52) | CHRNA7CHRM3CHRNB2CHRNA4ACHE | |
| Hydrochloric Acid SCHEMBL11194479 | 0.86 | CHRNA7 (0.47) | CHRNA7CHRM3CHRNB2CHRNA4ACHE | |
| SCHEMBL4256635 | 0.85 | CHRNA7 (0.45) | CHRNA7CHRM3ACHECHRM2 | |
| Trifluoromethanesulfonic Acid SCHEMBL8349313 | 0.83 | CHRNA7 (0.39) | CHRNA7CHRM3ACHECHRM2 | |
| Iodide SCHEMBL3691022 | 0.80 | CHRNA7 (0.63) | CHRNA7CHRM3CHRNB2CHRNA4CHRM2 | |
| SCHEMBL10257199 | 0.80 | KCNH2 (0.48) | CHRNA7CHRM3CHRM2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2025-02-20 | — | — | US | disclosed |
| US-11603368-B2 | Fused thiophene derivatives and their uses | ENYO PHARMA (FR) | 2023-03-14 | — | — | US | disclosed |
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2022-08-25 | — | — | US | disclosed |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| EP-3749658-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO Pharma (FR) | 2020-12-16 | — | — | EP | disclosed |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2020-11-26 | — | — | US | disclosed |
| EP-3312172-B1 | AMINOPYRAZOLE DERIVATIVES USEFUL AS SRC KINASE INHIBITORS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2020-05-06 | — | — | EP | disclosed |
| US-10479780-B2 | Aminopyrazole derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-11-19 | — | — | US | disclosed |
| WO-2019154949-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | ENYO PHARMA (FR) | 2019-08-15 | — | — | WO | disclosed |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20080214827-A1 | For severe and chronic pain; 1-(1-Cyclooctyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-ylidene-cyanamide and 2-[2-Cyanoimino-3-(1-cyclooctyl-piperidin-4-yl)-2,3-dihydro-benzoimidazol-1-yl]-acetamide | EURO-CELTIQUE S.A. (US) | 2008-09-04 | — | — | US | disclosed |
| EP-1420020-B1 | 4-OXOIMIDAZOLIDINE-2-SPIROPIPERIDINE DERIVATIVE | BANYU PHARMA CO LTD (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1831165-A1 | 4-AMINOPIPERIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007053498-A1 | COMPOUNDS USEFUL AS ANTAGONISTS OF CCR2 | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2007-04-05 | — | — | US | disclosed |
| US-7192964-B2 | 4-oxoimidazolidine-2-spiropiperidine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-03-20 | — | — | US | disclosed |
| WO-2006066747-A1 | 4-AMINOPIPERIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135561-A1 | 4-Aminopiperidine derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2006-06-22 | — | — | US | disclosed |
| US-20050004363-A1 | 4-oxoimidazolidine-2-spiropiperidine derivatives | MSD K.K. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-1420020-A1 | 4-OXOIMIDAZOLIDINE-2-SPIROPIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2004-05-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220267318-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | CHRM3 4035/4885ACHE 2753/4885CHRNA7 3220/4885 |
| US-20070078153-A1 | 4-Oxoimidazolidine-2-spiropiperidine derivatives | OPRL1, OPRK1, OPRD1 | CHRM3 385/4885ACHE 823/4885CHRNA7 298/4885 |
| US-10479780-B2 | Aminopyrazole derivatives | SRC, GRK2, GRK3 | CHRM3 1952/4885ACHE 4458/4885CHRNA7 2930/4885 |
| US-20050004363-A1 | 4-oxoimidazolidine-2-spiropiperidine derivatives | OPRL1, OPRD1, OPRK1 | CHRM3 376/4885ACHE 884/4885CHRNA7 295/4885 |
| US-20200369682-A1 | FUSED THIOPHENE DERIVATIVES AND THEIR USES | FTH1, SLC40A1, FECH | CHRM3 4870/4885ACHE 4712/4885CHRNA7 4885/4885 |
| US-20250059181-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | CHRM3 4035/4885ACHE 2753/4885CHRNA7 3220/4885 |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | CHRM3 4035/4885ACHE 2753/4885CHRNA7 3220/4885 |
| US-20060135561-A1 | 4-Aminopiperidine derivatives | DPP4, GPR119, IAPP | CHRM3 572/4885ACHE 735/4885CHRNA7 1109/4885 |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | PIK3CA, PIK3CD, PIK3CB | CHRM3 4429/4885ACHE 3157/4885CHRNA7 2766/4885 |
| US-20080214827-A1 | For severe and chronic pain; 1-(1-Cyclooctyl-piperidin-4-yl)-1,3-dihydro-benzoimidazol-2-ylidene-cyanamide and 2-[2-Cyanoimino-3-(1-cyclooctyl-piperidin-4-yl)-2,3-dihydro-benzoimidazol-1-yl]-acetamide | CNR2, CNR1, TRPV1 | CHRM3 706/4885ACHE 265/4885CHRNA7 328/4885 |
| US-11603368-B2 | Fused thiophene derivatives and their uses | FTH1, SLC40A1, FECH | CHRM3 4870/4885ACHE 4712/4885CHRNA7 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.